


Allopurinol linked to reduced risk for CKD stage ≥ 3 in gout

October 25 2018



(HealthDay)—For patients with gout, allopurinol is associated with a

reduced risk for developing chronic kidney disease stage ≥ 3 , according to a study published online Oct. 8 in *JAMA Internal Medicine*.

Ana Beatriz Vargas-Santos, M.D., from the State University of Rio de Janeiro, and colleagues conducted a propensity score-matched, population-based prospective cohort study of individuals with newly diagnosed gout who initiated allopurinol ≥ 300 mg/day versus those who did not initiate allopurinol. A total of 4,760 initiators of allopurinol were propensity score-matched with the same number of non-initiators.

The researchers found that 579 allopurinol initiators and 623 non-initiators developed chronic kidney disease stage ≥ 3 , with a mean follow-up of five and four years, respectively. Compared with non-users, allopurinol use ≥ 300 mg/day was correlated with a lower risk for developing [chronic kidney disease](#) stage ≥ 3 (hazard ratio, 0.87; 95 percent confidence interval, 0.77 to 0.97). There was no significant correlation between allopurinol initiation

Citation: Allopurinol linked to reduced risk for CKD stage ≥ 3 in gout (2018, October 25) retrieved 17 May 2024 from <https://medicalxpress.com/news/2018-10-allopurinol-linked-ckd-stage-gout.html>

<p>This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.</p>
--